anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention concerns nucleotides vaccines encoding influenza proteins with few or no glycosylation sites. Since these first introductions of pandemic influenzas the viruses have drifted, accumulating mutations at antigenic sites, but also the N-glycosylation pattern has changed during the drifted years, accumulating N-linked glycosylation sequons that help mask the antigenic sites for recognition by the host immune system. These "naked" initial haemagglutinins induce a broad cross reactivity against widely drifted influenza subtypes. The origin of the DNA or RNA can be both pandemic influenza strains, which codes for proteins which have a naturally low content of glycosylation sites and/or DNA or RNA from non-pandemic influenza strains where the nucletides have been mutated or changed so it encodes for proteins with less or no glycosylation sites. The invention also discloses DNA or RNA encoding the haemagglutinin (HA) from pandemic influenza A, e.g. the 1918 H1N1 and/or the 1957 H2N2 and/or the 1968 H3N2 influenza A virus,, optionally with the Neuraminidase (NA) and/or matrix protein (M) and/or the nucleoprotein (NP) from these pandemic influenza virus included, mixed together with DNA or RNA from non-pandemic influenza A as a vaccine against present day and future influenza A viruses.
PROBLEM TO BE SOLVED: To obtain the subject granules with suppressed bitterness and irritancy, easy to take, stable with time, and useful as an anti-inflammatory/analgesic agent or the like, by adding a vehicle to coated ibuprofen-contg. granules prepared by coating an ibuprofen-contg. mixture with an enteric polymeric compound followed by conducting a granulation. SOLUTION: This granules is obtained by incorporating coated ibuprofen- contg. granules prepared by coating (A) an ibuprofen-contg. mixture with (B) an enteric polymeric compound such as a methacrylic acid copolymer with (C) a vehicle such as D-mannitol followed by conducting a granulation; wherein as other active ingredients in the ingredient A, (D) an ingredient good in compatibility with ibuprofen (pref. potassium guaiacolsulfonate or the like) and (E) another ingredient poor in compatibility with ibuprofen (pref. ascorbic acid or the like) are usable, and it is preferable that granulates afforded using the ingredient D and those afforded using the ingredient E are mixed with each other, and the active ingredients are pref. formulated at 20-50 wt.% based on the whole amount of the final granules.
Viral Infections

Chickenpox and measles can have a more serious or even fatal course in pediatric and adult patients on corticosteroids. In pediatric and adult patients who have not had these diseases, particular care should be taken to avoid exposure. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with immune globulin (IG) may be indicated. (See the respective package inserts for VZIG and IG for complete prescribing information.) If chickenpox develops, treatment with antiviral agents should be considered.
Primary biliary cholangitis (PBC) is a progressive and uncommon inflammatory autoimmune cholesteric liver disease，which will contribute to cirrhosis. Symptoms and course of primary biliary cholangitis can be diverse, wherefore the targets of the current treatment are focused on the prevention of end-stage liver disease. Researches reported patients with PBC may involve abnormalities on skeleton, thyroid and exocrine glands. However, whether this autoimmune disease would cause cardiac impairment is scarcely investigated. From our clinical practice, the cardiac structural abnormal can be found in certain patients with PBC detected by cardiovascular magnet resonance (CMR). CMR is the primary and emerging imaging modality for myocardial tissue characterization, and it is recommended as a gold standard for functional imaging and assessment. This three-center, multi-modality, prospective observational study plans to identify the type and the severity of cardiac changes in PBC.
ABSTRACT OF THE DISCLOSURE         The disclosure describes a process for the production of an attenuated strain of measles virus effective for the production of an attenuated measles virus vaccine.  The starting material is an Edmonston strain of measles virus which has undergone a plurality of culture passages in various culture media.  A sample of the last culture passage is taken and a plurality of culture passages of the sample is effected in primary cultures of fibroblasts of chicken embryos.  A sample from the last culture passage is inoculated and a culture pas-sage is effected in a primary culture of fibroblasts of chicken embryos thereby obtaining clones of virus.  Clones of measles virus obtained in the last culture passage are isolated and one selects those which are thermosensitive at a temperature between about 32°C and 37°C.  Among the thermosensitive clones which have been selected, another selection is made of the ones with moderate cytopathic effect, and finally one isolates from the latest selection, the one which shows highest seroconversion on monkeys, thus producing an attenuated strain of measles virus.
PROBLEM TO BE SOLVED: To obtain a composition for inhibiting or remedying symptoms involved in homeostasis depressions including poor circulation, menopausal disorders, sleep disorder and autonomic ataxia by including theanine. SOLUTION: This composition is obtained by including pref. 0.00025-100 wt.% of theanine (a glutamic acid derivative found in tea leaves, being the main ingredient of the deliciousness of tea). The daily dose of theanine is pref. 0.2-2,000 mg/kg for sufficiently exhibiting homeostasis depression inhibitory effect; for example, for the purpose of sufficiently exhibiting the remedying effect for poor circulation, menopausal disorders, or sleep disorder, its daily dose is pref. 0.2-200 mg/kg. The use mode of this composition is pref. a food composition or pharmaceutical composition.
OBJECTIVES: Despite the popularity of the frozen elephant technique procedure in recent years, evidence is scarce regarding its utilization for aortic arch replacement following previous acute aortic dissection repair. In this systematic review and meta-analysis, we aimed to analyse clinical outcomes of aortic arch replacement in patients with previous repair of acute aortic dissection.
METHODS: A systematic literature search on PubMed, MEDLINE via Ovid, Embase, Scopus, and Web of Science until March 2024 was performed for studies on open aortic arch replacement with or without frozen elephant technique procedure in adult patients after previous acute aortic dissection repair. Early and late postoperative mortality were primary, while postoperative complications were secondary outcomes of interest. Additionally, a meta-analysis was performed to pool the early and late postoperative mortality.
RESULTS: A total of 574 studies were identified, of which 9 studies including a total of 677 patients met the eligibility criteria. In-hospital or 30-day postoperative mortality and stroke were 0-17.5% and 0-7.7%, respectively. Duration of follow-up across all studies varied from 1.1 to 5.1 years. All-cause late mortality rate ranges from 5.9% to 30.5%. Aortic reintervention rate was 4.8-38.7%. The pooled early and late mortality rate were 8.7% [95% confidence interval (CI) 5.7-13%; I2 = 52%] and 24.9% (95% CI 19.5-31.1%; I2 = 54%), respectively.
CONCLUSIONS: Current evidence suggest that relatively younger patients with chronic post-dissection aneurysm or residual aortic dissection after acute aortic dissection repair can undergo an aortic arch replacement by a dedicated aortic team with acceptable mortality risk. However, postoperative neurological deficit remains an issue.
During central line insertion, After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 30-40 degree.
Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine was injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection was determined by the investigator. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine was injected on Day 14.
The invention relates to a method for identifying and/or producing an inhibitor of hair growth. The invention also relates to a method for inhibiting hair growth and to a method for producing a medicament. The invention further relates to a medicament, which comprises an inhibitor of hair growth that is identified or obtained according to one of the inventive methods or to a polynucleotide that codes for an inhibitor, optionally in a pharmaceutically compatible dosage form. The invention also relates to a medicament, which contains a polypeptide comprising the DNA bonding domain but not the transactivator domain of Whn, LEF-1 or Hoxc13 or a polynucleotide that codes for said polypeptide, optionally in a pharmaceutically compatible dosage form. In addition, the invention relates to the use of a polypeptide that contains the DNA bonding domain, but not the transactivator domain of Whn, LEF-1 or Hoxc13 or a polynucleotide that codes for said polypeptide, the use of an inhibitor, which is identified and/or obtained according to one of the inventive methods or of a polynucleotide, which codes for an inhibitor of this type, for producing a medicament for treating hair-growth disorders. Finally, the invention relates to a kit for carrying out the inventive method.
Psychoeducation focusing on alcohol use: This support program provides 8 brief modules of psychoeducation (alcohol information) over 10 weeks. Participants receive no therapist guidance/support but have the possibility of asking questions to a therapist. There are two separate programs for the young adult and the caregiver/significant other.
Safety and effectiveness of SYMBICORT in asthma patients 12 years of age and older have been established in studies up to 12 months. In the two 12-week, double-blind, placebo-controlled US pivotal studies 25 patients 12 to 17 years of age were treated with SYMBICORT twice daily [see Clinical Studies (14.1)]. Efficacy results in this age group were similar to those observed in patients 18 years and older. There were no obvious differences in the type or frequency of adverse events reported in this age group compared with patients 18 years of age and older. 

The safety and effectiveness of SYMBICORT 80/4.5 in asthma patients 6 to less than 12 years of age have been established in studies of up to 12-week duration [see Clinical Studies (14.1)]. The safety profile in these patients was consistent to that observed in patients 12 years of age and older who also received SYMBICORT [see Adverse Reactions (6.1)].

The safety and effectiveness of SYMBICORT in asthma patients less than 6 years of age have not been established.

Controlled clinical studies have shown that orally inhaled corticosteroids including budesonide, a component of SYMBICORT, may cause a reduction in growth velocity in pediatric patients. This effect has been observed in the absence of laboratory evidence of HPA-axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA-axis function. The long-term effect of this reduction in growth velocity associated with orally inhaled corticosteroids, including the impact on final height are unknown. The potential for “catch-up” growth following discontinuation of treatment with orally inhaled corticosteroids has not been adequately studied. 

In a study of asthmatic children 5 to 12 years of age, those treated with budesonide DPI 200 mcg twice daily (n=311) had a 1.1 centimeter reduction in growth compared with those receiving placebo (n=418) at the end of one year; the difference between these two treatment groups did not increase further over three years of additional treatment. By the end of 4 years, children treated with budesonide DPI and children treated with placebo had similar growth velocities. Conclusions drawn from this study may be confounded by the unequal use of corticosteroids in the treatment groups and inclusion of data from patients attaining puberty during the course of the study. 

The growth of pediatric patients receiving orally inhaled corticosteroids, including SYMBICORT, should be monitored. If a child or adolescent on any corticosteroid appears to have growth suppression, the possibility that he/she is particularly sensitive to this effect should be considered. The potential growth effects of prolonged treatment should be weighed against the clinical benefits obtained. To minimize the systemic effects of orally inhaled corticosteroids, including SYMBICORT, each patient should be titrated to the lowest strength that effectively controls his/her asthma [see Dosage and Administration (2)].
Stable, freeze-dried, pharmaceutically acceptable compsns. comprises a protein, a buffer, alanine and mannitol. The mannitol/alanine wt. ratio is 0.1-1. The protein is speical a protein having bioactivity, such as hormone, speical hGH, enzyme  or cytokinin,  Also claimed is a test kit comprising a compsn. as above.
Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity.
This group will receive the new phenylalanine-free protein substitute daily for 28 days. Patients in this group intervention will be directed to consume one powder sachet (33 g) of daily made up with 100mL of water. The new substitute delivers 414 kJ, 20g protein equivalent and a combination of essential and non-essential amino acids as well a combination of vitamins and minerals.
If the participant qualifies to take part in this research study, they will be asked to participate in 15-190 study visits,to complete the experimental procedures. These procedures have been broken up into "Phases" and will be completed in any order. Phase I and Phase IIa includes 2-30 total visits - approximately 2-3 hours each to measure arm and finger strength and ability to move. Phase IIb includes 2-30 total visits - approximately 2-3 hours each, to measure leg strength and ability to move. Phase IIIa includes up to 40 total visits - approximately 2 hours each, the investigator will again evaluate the participant's ability to use both arms. The participant will be asked to complete a series of tasks such as stacking checkers, turning over cards, squeeze a device to determine how strong their grip is, and see how well they are able to feel sensations on the surface of their skin. The investigators will complete these assessments at pre-determined times during the study participation. Phase IIIb includes up to 40 total visits - approximately 2 hours each, the investigator will again evaluate the participant's ability to use both legs. Assessments of the participant's legs will include walking around the lab space, how well they can bend their ankles and hips, and how well they are able to feel sensations on the surface of the participant's skin.
BACKGROUND/AIM: We employed Mendelian randomization (MR) analysis to investigate the causal relationship between the gut microbiota, acute pancreatitis, and potential inflammatory proteins.
METHODS: The data for gut microbiota, acute pancreatitis, and inflammatory proteins are sourced from public databases. We conducted a bidirectional MR analysis to explore the causal relationship between gut microbiota and acute pancreatitis, and employed a two-step MR analysis to identify potential mediating inflammatory proteins. IVW is the primary analysis method, heterogeneity, pleiotropy, and sensitivity analyses were also conducted simultaneously.
RESULTS: We identified five bacterial genera associated with the risk of acute pancreatitis, namely genus.Coprococcus3, genus.Eubacterium fissicatena group, genus.Erysipelotrichaceae UCG-003, genus.Fusicatenibacter, and genus.Ruminiclostridium6. Additionally, we have discovered three inflammatory proteins that are also associated with the occurrence of acute pancreatitis, namely interleukin-15 receptor subunit alpha (IL-15RA), monocyte chemoattractant protein-4 (CCL13), and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Following a two-step MR analysis, we ultimately identified IL-15RA as a potential intermediate factor, with a mediated effect of 0.018 (95% CI: 0.005 - 0.032).
CONCLUSION: Our results support the idea that genus.Coprococcus3 promotes the occurrence of acute pancreatitis through IL-15RA. Furthermore, there is a potential causal relationship between the gut microbiota, inflammatory proteins, and acute pancreatitis. These findings provide new insights for subsequent acute pancreatitis prevention.
Obesity is epidemic and of great concern because of its comorbid and costly inflammatory-driven complications. Extensive investigations in mice have elucidated highly coordinated, well-balanced interactions between adipocytes and immune cells in adipose tissue that maintain normal systemic metabolism in the lean state, while in obesity, proinflammatory changes occur in nearly all adipose tissue immune cells. Many of these changes are instigated by adipocytes. However, less is known about obesity-induced adipose-tissue immune cell alterations in humans. Upon high-fat diet feeding, the adipocyte changes its well-known function as a metabolic cell to assume the role of an immune cell, orchestrating proinflammatory changes that escalate inflammation and progress during obesity. This transformation is particularly prominent in humans. In this review, we (a) highlight a leading and early role for adipocytes in promulgating inflammation, (b) discuss immune cell changes and the time course of these changes (comparing humans and mice when possible), and (c) note how reversing proinflammatory changes in most types of immune cells, including adipocytes, rescues adipose tissue from inflammation and obese mice from insulin resistance.
Reports of tubulointerstitial nephritis with medullary calcification and cortical atrophy have been observed in patients with asymptomatic severe leukocyturia (>100 cells/ high power field). Patients with asymptomatic severe leukocyturia should be followed closely and monitored frequently with urinalyses. Further diagnostic evaluation may be warranted, and discontinuation of CRIXIVAN should be considered in all patients with severe leukocyturia.

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including CRIXIVAN. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.

Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.
It has been concluded 40%-70% of chronic hepatitis B patients can achieve fibrosis/ cirrhosis reversion after effective anti-viral therapy. But there is still some patients progress to decompensation. Esophageal varices are the main complication of cirrhotic patients. Propranolol are widely used to prevent variceal bleeding in patients with large esophageal varices. It has been shown the efficacy of propranolol in the preventing of the progression from small to large varices reported no effect. Recently, carvedilol has been shown to be more potent in decreasing portal hypertension to propranolol. But the efficacy of carvedilol to delay the growth of esophageal varices in chronic hepatitis B patients was unclear. The purpose of this study is to demonstrate the efficacy of carvedilol in the preventing of the progression from small to large varices in hepatitis B patients.
The disclosure relates to a mineral sunscreen composition having a synergistic combination of a mineral sunscreen agent and a film former. The mineral sunscreen agent may include titanium dioxide, zinc oxide, or combinations thereof. The film former may be selected from polyester copolymers. For example, the polyester copolymers may include octyldodecyl citrate crosspolymer. The mineral sunscreen composition may further include a non-aqueous diluent. The non-aqueous diluent may include a hydrocarbon. The sunscreen composition may be in the form of a lotion, a spray, or combinations thereof.
WNT subgroup medulloblastoma patients accrued in the study will be treated with Low-dose Craniospinal Irradiation (18Gy/10fx) plus focal conformal tumor-bed boost (36Gy/20fx) for total primary-site dose of 54Gy/30fx over 6-weeks. Followed by adjuvant multi-agent systemic chemotherapy which will be initiated 4-6 weeks after completion of radiotherapy provided the ANC \>1500 and platelet count \>1,00,000. A total of 6 cycles of alternating chemotherapy every 4-weekly will be planned as per our standard practice using CET protocol.
The invention relates to substituted benzylidene tetralone derivatives and a preparation method and application. The chemical structural formula of the substituted benzylidene tetralone derivatives is shown in the formula (1) in the specification, and in the formula (1), X represents CHOH or C=O, and R represents any one of H, OH, F, Cl, CN, CONH2, NO2, CH3, OCH3 and NH2. In the synthetic route, any substitution group can be introduced into two benzene rings, thus eliminating the limit on organic synthesis for finding out compounds with better activity. After water-soluble groups such as amino and the like are introduced, the water solubility can be greatly improved compared with a pilot compound CA-4, and the research of druggability is facilitated. In addition, after amino, hydroxyl and the like are introduced, not only can the bioactivity be improved, but also a prodrug can be prepared on the basis of the group, and the in-vivo activity study can be favorably conducted. The derivatives have the effects of treating ovarian cancer, colon cancer, thyroid cancer and leukemia.
PURPOSE:To provide the titled hair shampoo giving natural luster to the hair without damaging the scalo and hair, by drying the stalk and leaf of SANEKAZURA (Kadsura japonica) to a water content lower than a specific level, and collasping the tissue of the vegetable. CONSTITUTION:The objective hair shampoo is prepared by drying the stalk and leaf of SANEKAZURA to a water content of <=50wt%, and collapsing the tissue of the vegetable. Most hair shampoos are composed mainly of synthetic detergents, which are effective to remove the stain from the hair but sometimes cause the damage of the hair by removing the useful fat components of the scalp and hair by the strong detergent power. The juice of SANEKAZURA contains various enzymes such as lipase, protease, etc. as well as polysaccharides, which act synergistically to remove the stain from the scalp and hair without damaging the same. Furthermore, the agent gives natural softness and luster to the hair to facilitate the hair dressing.